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Abstract
Background: Monitoring of immunosuppressive drugs 
such as everolimus and sirolimus is important in allograft 
rejection prevention in transplant patients. Dried blood 
spots (DBS) sampling gives patients the opportunity to 
sample a drop of blood from a fingerprick at home, which 
can be sent to the laboratory by mail.
Methods: A total of 39 sirolimus and 44 everolimus paired 
fingerprick DBS and whole blood (WB) samples were 
obtained from 60 adult transplant patients for method 
comparison using Passing-Bablok regression. Bias was 
assessed using Bland-Altman. Two validation limits were 
pre-defined: limits of analytical acceptance were set at 
>67% of all paired samples within 20% of the mean of 
both samples and limits of clinical relevance were set in 
a multidisciplinary team at >80% of all paired samples 
within 15% of the mean of both samples.
Results: For both sirolimus and everolimus, Passing-
Bablok regression showed no differences between WB 
and DBS with slopes of 0.86 (95% CI slope, 0.72–1.02) and 
0.96 (95% CI 0.84–1.06), respectively. Only everolimus 
showed a significant constant bias of 4%. For both siroli-
mus and everolimus, limits of analytical acceptance were 
met (76.9% and 81.8%, respectively), but limits or clinical 
relevance were not met (77.3% and 61.5%, respectively).
Conclusions: Because pre-defined limits of clinical rel-
evance were not met, this DBS sampling method for siroli-
mus and everolimus cannot replace WB sampling in our 
center at this time. However, if the clinical setting is com-
patible with less strict limits for clinical relevance, this 
DBS method is suitable for clinical application.
Keywords: dried blood spots; immunosuppressants; 
microsampling; validation.
Introduction
Lifelong therapy with immunosuppressive drugs is a cor-
nerstone in the prevention of rejection of allografts in 
transplant patient care [1]. Because of their narrow thera-
peutic range, many immunosuppressive drugs, including 
the mammalian target of rapamycin inhibitors everolimus 
and sirolimus are subject to therapeutic drug monitor-
ing (TDM) to allow for balancing between toxic- and sub-
therapeutic drug concentrations. Tacrolimus is currently 
the most widely used calcineurin inhibitor in kidney 
transplant patient care [2]. However, the recent TRANS-
FORM trial suggests efficacy of maintenance therapy with 
everolimus in combination with low dose tacrolimus is 
comparable to a standard regimen of tacrolimus and 
mycophenolate mofetil [3, 4]. An additional advantage 
is the reduced viral infection risk. This might lead to an 
increase in everolimus use in transplant patients.
Traditionally, venous blood samples are used for 
monitoring of immunosuppressive drug concentrations 
and patients have to travel to the hospital on a regular 
basis to have their blood drawn. To decrease the burden 
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for patients, dried blood spot (DBS) home sampling 
has been developed among various micro sampling 
methods for several drugs, including immunosuppres-
sants, to enable home sampling [5–16]. For this, a drop 
of blood from a fingerprick is applied to a sampling card 
and dried. This card is sent to the laboratory by mail a 
few days prior to routine check-up of the patient in the 
hospital. At the time of the check-up, blood-drug con-
centrations and creatinine levels will be available for 
the clinician and the patient. Current challenges of DBS 
implementation include the influence of the hematocrit 
and logistical hurdles [9, 13, 17, 18]. Although DBS analyti-
cal methods can meet the required analytical standards, 
analysis of clinically collected samples does not always 
result in sufficient agreement between the standard 
(venous) method and the novel fingerprick DBS method 
[17]. Therefore, a clinical validation study showing inter-
changeability between DBS and venous sampling is 
required before clinical application [18]. This is shown 
for tacrolimus, cyclosporin A and creatinine [5, 7–15, 19]. 
For sirolimus, Dickerson et al. report agreement between 
fingerprick DBS and venous samples in 25 pediatric trans-
plant patients, where mean DBS concentrations were on 
average 0.8 μg/L lower than venous samples [15]. This dif-
ference between the two methods increased with increas-
ing concentrations of sirolimus. Willemsen et al. reported 
agreement between everolimus fingerprick DBS and 
venous samples in 20 patients with cancer with a mean 
ratio of whole blood (WB) to DBS concentrations of 0.90 
[20]. The current Clinical and Laboratory Standards Insti-
tute (CLSI) guideline suggests at least 40 paired samples 
for comparison, therefore, the number of samples col-
lected in both studies for cross-validation was low [21]. 
In addition, no clinical validation study for everolimus 
using fingerprick DBS has been published for transplant 
patients. Therefore, the aim of this study was to clinically 
validate our method for analyzing sirolimus and everoli-
mus in DBS to enable implementation in routine care.
Materials and methods
Patients and sample collection
Patient samples were collected from adult transplant patients dur-
ing routine clinical check-ups in the hospital. Because of the nature 
of this study, the need to provide written informed consent by the 
patients was waived by the Ethics Committee of the University 
Medical Center Groningen (Metc 2011.394). A trained phlebotomist 
obtained both the venous and DBS samples within 10 min of each 
other using a collection method described elsewhere [9, 22, 23]. In 
short, after a fingerprick, two drops of blood were allowed to fall 
freely on a Whatman FTA DMPK-C sampling paper (GE Healthcare, 
Chicago, IL, USA). The WB samples were analyzed within a day as 
they were part of routine care. DBS are stable for at least 7 days at 
room temperature, therefore the DBS samples were allowed to dry 
for 24–74 h at room temperature and packed in zip lock plastic mini 
bags with a desiccant [24–26]. Upon receiving the DBS samples in the 
laboratory, the samples were inspected for spot quality based on pre-
defined criteria [22, 23, 27]. DBS samples fit for analysis were stored 
at −20 °C until analysis. DBS samples are stable for at least 29 weeks 
at −20 °C so analysis occurred within this timeframe [25].
Equipment, conditions and procedures
Our reference procedure was a measurement of sirolimus and 
everolimus in WB obtained by venipuncture, with a previously 
validated analysis method performed on a Thermo Fisher Scientific 
(Waltham, MA, USA) triple quadrupole Quantiva LC-MS/MS system 
with a Vanquish HPLC system [28]. For the DBS analysis of sirolimus 
and everolimus, a previously validated method was used using the 
aforementioned Thermo Quantiva LC-MS/MS [24, 25]. The analytical 
range for both the WB and DBS assay for sirolimus and everolimus 
was 1.0–50.0 μg/L.
Hematocrit of the venous samples was measured using an 
XN10/XN20 hematology analyzer (Sysmex, Kobe, Japan).
Statistical analysis
Statistical analysis was performed using Analyse-it® Method Valida-
tion Edition for Microsoft Excel version 4.18.6 (Analyse-it, Leeds, UK) 
and Microsoft Excel (Microsoft Inc., Redmond, WA, USA). Method 
comparison was done using Passing-Bablok regression analysis 
and a Bland-Altman analysis was used for bias calculation [29, 30]. 
Because no official guideline exists for clinical validation of DBS 
assays, we set two limits of acceptance a priori. The first is the limit 
of analytical acceptance which is based on the EMA guidelines for 
cross-validation and the 2018 version of the FDA guideline for  studies 
required to bridge two analytical methods [31, 32]. As acceptance 
criteria, both FDA and EMA guidelines state that at least two-thirds 
(67%) of the paired samples should be ±20% of the mean of both 
methods. The second is the limit of clinical relevance which was set 
at a range of 85%–115% around the ratio of the paired DBS and WB 
samples for at least 80% of the samples. This range was chosen by 
a multidisciplinary team consisting of clinicians, pharmacists and 
analysts and was chosen based on the therapeutic window given in 
the summary of product characteristics of 3–8 μg/L for everolimus 
and 4–12 μg/L for sirolimus trough concentrations for stable trans-
plant patients >3 months after transplantation [33, 34]. A difference 
of 15% in the acceptable range ratio for a high everolimus trough 
concentration (8 μg/L) in WB would lead to a DBS concentration 
range of 6.8–9.2 μg/L. For a low everolimus trough concentration 
(3 μg/L) in WB this would lead to an acceptable DBS concentration 
range of 2.6–3.5 μg/L. These values are comparable to the acceptable 
variability of 15% for accuracy and precision that are mentioned in 
the FDA and EMA guidelines for bioanalytical methods [31, 32]. If 
80% of all patients are within this range this was deemed feasible 
by the clinicians.
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The predictive performance of the DBS analytical method was 
established using the method described by Sheiner and Beal [35]. In 
short, DBS concentrations were used to predict WB concentrations. 
For each paired WB and DBS sirolimus and everolimus sample, the 
slope and intercept of the Passing-Bablok regression was calculated 
using the whole population of sirolimus and everolimus samples, 
respectively, excluding the data of that specific paired sample. The 
error of this prediction is determined by bias and imprecision. The 
bias is the median difference between the predicted and true con-
centration and is shown by the median prediction error (MPE) and 
the median percentage prediction error (MPPE). The imprecision is 
the variance of the predicted values which is measured by the root 
median squared prediction error (RMSE) and the median absolute 
percentage prediction error (MAPE). For analyzing the predictive 
 performance the following equations were used:
 = −median prediction error  (MPE) median (predicted WB WB) (1)
 
median percentage prediction  error (MPPE)





∗    (2)
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root median squared prediction error (RMSE)  





median absolute percentage prediction error (MAPE)





∗    (4)
In accordance with other studies, acceptable values for MPPE and 
MAPE were set at <15% and at least 67% of all samples should have 
an absolute prediction error of <20% [5, 20].
Results
Patients and samples
A total of 90 paired DBS and WB samples were taken from 
60 adult transplant patients between January 2017 and 
December 2017. All DBS cards had at least one spot of suf-
ficient quality for analysis. Three samples were excluded 
because no paired WB sample was taken. Another three 
samples were excluded because the WB and DBS sample 
were not taken within 10 min of each other. One sample 
was excluded because it was not a trough concentration. 
A total of 39 paired sirolimus and 44 paired everolimus 
samples were available for method comparison from 29 
and 27 unique transplant patients, respectively. The hema-
tocrit ranged from 0.23 to 0.51 (v/v) with a mean hematocrit 
of 0.40. All hematocrit values were within the analytically 
validated range, which means that the hematocrit value 
had no influence on the DBS analytical results [24]. Mean 
concentrations of sirolimus and everolimus in WB and 
DBS can be found in Table 1. All evaluated concentrations 
were within the analytically validated range [24]. Patient 
demographics and transplantation type can be found in 
Tables 2 and 3.
Clinical validation
Sirolimus
For sirolimus, the Passing-Bablok analysis fit was 
y = 0.86x + 0.44 (95% CI slope, 0.72–1.02; 95% CI intercept 
−0.23 to 1.11) showing no significant constant or system-
atic difference as can be seen in Figure 1. The correlation 
coefficient was 0.93. The Bland-Altman plot (Figure  2) 
shows that the mean ratio of WB and DBS sirolimus con-
centrations is 1.00 (95% CI 0.93–1.07), without significant 
bias. The 95% limits of agreement (LoA) are 0.60 and 1.40, 
which is wider than the limits of analytical acceptance 
which were set at 0.80 and 1.20. Nine out of 39 values 
Table 1: Mean drug concentrations, range and SD of sirolimus and 
everolimus in WB and DBS.
Drug concentrations n Mean ± SD (range)
Sirolimus in WB, μg/L 39 5.0 ± 2.4 (1.9–10.9)
Sirolimus in DBS, μg/L 39 4.7 ± 1.9 (1.8–9.7)
Everolimus in WB, μg/L 44 5.4 ± 2.6 (1.2–14.3)
Everolimus in DBS, μg/L 44 5.0 ± 2.4 (1.9–10.9)
DBS, dried blood spot; SD, standard deviation; WB, whole blood.
Table 2: Patient demographics and transplantation type.
Patient demographics and 
clinical laboratory data
  n   Median (range)
Age, years   56   61 (23–77)
Sex   56   38 male (67.9%),  
18 female (32.1%)
Time from transplantation  56   2 years, 3 months, 5 days 
(10 days–22 years, 7 months)











Liver   30  0  30  22
Lung   2  7  9  7
Stem cell   7  0  7  6
Kidney   0  37  37  21
Total   39  44  83  56
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(23.1%) fell outside the limits of analytical acceptance. For 
the limits of clinical relevance this was 15/39 (38.5%). For 
the predictive performance, bias was small with an MPE of 
−0.008 μg/L and an MPPE of −0.16%. The predictive perfor-
mance of imprecision as measured by the RMSE was small 
with a value of 0.56 μg/L. The MAPE was within accept-
able limits (<15%) with a value of 11.07%. The acceptance 
limit for MAPE (at least 67% of the samples with a value 
<20%) was met with 30 out of 39 values (76.9%) (Figure 3).
Everolimus
For everolimus, the Passing-Bablok analysis fit was 
y = 0.96x + 0.37 (95% CI slope, 0.84–1.06; 95% CI inter-
cept −0.11 to 0.99), also showing no significant con-





























Sirolimus: whole blood, µg/L
Figure 1: Method comparison for sirolimus concentrations in WB 
and DBS (n = 39).
The continuous line is the Passing-Bablok regression line 
y = 0.86x + 0.44 (95% CI slope, 0.72–1.02; 95% CI intercept −0.23 to 



































Figure 2: Method comparison for sirolimus concentrations in WB and DBS (n = 39).
The continuous line is the Bland-Altman bias estimation of 1.00 (95% CI 0.93–1.07). The dashed line is the 95% LoA and the dotted/dashed 






















Measured sirolimus concentration in whole blood, µg/L
Percentage predication error of predicted to measured sirolimus concentration in µg/L
Figure 3: Percentage prediction error or predicted to measured sirolimus concentrations with acceptable prediction error set at −20% and 20%.
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The  correlation coefficient was 0.97. The Bland-Altman 
plot (Figure 5) shows that the mean ratio of WB and DBS 
everolimus concentrations is 1.04 (95% CI 1.00–1.08), 
which is a small but significant bias of 4%. The 95% LoA 
are 0.78 and 1.30, which is wider than the limits of analyti-
cal acceptance which were set at 0.80 and 1.20. Only eight 
out of 44 values (18.2%) fell outside the limits of analytical 
acceptance. For the limits of clinical relevance this was 10 
out of 44 (22.7%). For the predictive performance, bias was 
small with an MPE of 0.003 μg/L and an MPPE of 0.13%. 
The imprecision as measured by the RMSE was small with 
a value of 0.39 μg/L. The MAPE was within acceptable 
limits (<15%) with a value of 7.9%. The acceptance limit 
for MAPE (at least 67% of the samples with a value <20%) 
was met with 39 out of 44 values (88.6%) (Figure 6). One 
outlier of −72.5% was observed. The outlier prediction 
error shown in Figure 6 can likely be explained by the low 
concentration of everolimus (1.2 μg/L in WB), which is just 
above the lower limit of quantification of the method. In 
this setting, the influence of the intercept (−0.49) becomes 
paramount, resulting in a predicted value of 0.33 μg/L, 
giving a prediction error of −72.5%.
Discussion
This study showed good agreement between DBS siroli-
mus and everolimus concentrations and venous WB con-
centrations in transplant patients over a concentration 
range relevant for TDM of trough concentrations. No cor-



































Everolimus: whole blood, µg/L
Figure 4: Method comparison for everolimus concentrations in WB 
and DBS (n = 44).
The continuous line is the Passing-Bablok regression line 
y = 0.96x + 0.37 (95% CI slope, 0.84–1.06; 95% CI intercept −0.11 to 
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Figure 5: Method comparison for everolimus concentrations in WB and DBS (n = 44).
The continuous line is the Bland-Altman bias estimation of 1.05 (95% CI 1.00–1.08). The dashed line is the 95% LoA and the dotted/dashed 






















Measured everolimus concentration in whole blood, µg/L
Percentage predication error of predicted to measured
everolimus concentration in µg/L
Figure 6: Percentage prediction error or predicted to measured 
everolimus concentrations with acceptable prediction error set at 
−20% and 20%.
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values. For sirolimus and everolimus 76.9% and 81.8%, 
respectively, of all DBS concentrations fell within limits 
of analytical acceptance. Therefore, this method met the 
requirements set in the EMA guideline for cross-validation 
and FDA guidelines for bridging studies [31, 32]. The pre-
dictive performance of the sirolimus and everolimus DBS 
method complied with the predefined criteria of >67% of 
all samples to have a prediction error of <20%. However, 
the limits set for clinical relevance (>80% of the samples 
with <15% of the mean) were not met with a value of 77.3% 
and 61.5% for sirolimus and everolimus, respectively.
Because tacrolimus is the most widely used immu-
nosuppressant in our center to prevent renal allograft 
rejection, the amount of patients in our institution receiv-
ing either sirolimus or everolimus is limited. Therefore, 
patients from all transplantation types (Table 3) were 
asked to provide samples. The heterogeneous patient pop-
ulation is a strength of this study, hematocrit values of all 
patients were within the analytically validated limits and 
mean hematocrit values were comparable between the 
different groups of transplant patients (data not shown).
Because a clinical validation of a DBS fingerprick 
method shows strong resemblance to a cross validation, 
the CLSI guideline recommends to include at least 40 
patient samples [21]. Although the study by Willemsen 
et  al. showed good agreement between WB and capil-
lary blood, the performed power calculation resulting 
in 20  samples necessary was done prior to this result. 
The power calculation was based on the assumption 
that venous blood and DBS are the same matrix and no 
effect of the hematocrit is expected [20]. It is, however, 
well-known that hematocrit can affect DBS assays and 
sometimes results in unacceptable biases [24, 25, 36]. 
Capillary collected blood consists of a mixture of venous 
blood, arterial blood and interstitial fluid which is not 
the same matrix as a venous WB sample. Therefore, we 
think making an assumption that the matrix of capillary 
blood is the same as venous WB is not recommended. 
Following the CLSI guideline for finding a sample size 
would, in our opinion, be more appropriate. The recom-
mendation of 40 samples in the CLSI guideline is based 
on regression analysis described by Linnet, where the 
amount of samples necessary for a cross-validation can 
be calculated based on the analytical characteristics 
of the assay [37]. If Linnets’ calculation would be fol-
lowed for the everolimus DBS assay used by Willemsen 
et al., the recommended number of samples is 40, and if 
Linnets’ calculation would be followed for the sirolimus 
DBS assay used by Dickerson et  al. the recommended 
number of samples is 37 [19, 36]. Because of the exclu-
sion of several sirolimus samples the required amount 
of 40  samples was not met. However, with the amount 
of 39 paired samples available, we do not think that the 
absence of one paired sample has a great influence on 
the clinical validation.
For everolimus, our results are in part in agreement 
with Willemsen et  al. [20]. Our method did not show a 
constant or proportional bias as shown by Willemsen 
et al. where a small but significant proportional bias was 
found in the Passing-Bablok regression. In addition, they 
demonstrated a ratio of 0.90 in the Bland-Altman com-
parison, where our method shows a small but statistically 
significant ratio of 1.04. It should be noted that the Bland-
Altman comparison by Willemsen et al. is shown as a ratio 
of WB/DBS which is in contrast with this study where the 
ratio is shown as DBS/WB. However, the spread of the rel-
ative difference in our method (Figure 5) and correspond-
ing LoAs are wider than in the method used by Willemsen 
et al. This is especially true for the low trough concentra-
tions (1–5 μg/L). Although not statistically significant, the 
analytical validation showed a trend towards more bias 
at lower concentrations (3 μg/L) compared to higher con-
centrations (10 μg/L) for everolimus [24]. This might be an 
explanation for the observed spread of relative difference. 
Other clinical validation studies usually have few samples 
and very few samples in the low concentrations range. 
However, in a study on tacrolimus, 22.2% (n = 63) of the 
lower (trough) concentrations exceeded ±20% limits of the 
DBS to WB concentration ratio [5]. In this study, the area 
under the curve (AUC) was calculated for both DBS and 
WB based on trough concentrations and three sampling 
points at t = 1, t = 2 and t = 3 h after medication intake. For 
the AUCs, 90.3% (n = 63) of the paired AUC values were 
within 20% limits of DBS to WB ratio suggesting higher 
tacrolimus concentrations show less spread compared to 
trough concentrations. It is unlikely that the hematocrit 
has caused these differences, because previous research 
shows that hematocrit effects are most prominent at high 
concentrations of everolimus and sirolimus (50 μg/L) 
and low hematocrits (<0.23 v/v) [24, 25]. Re-evaluation of 
the data stratified for either transplantation type or time 
from transplantations showed that these two factors are 
not of influence on the results (data not shown). In future 
studies, introduction of duplicate analysis of both WB and 
DBS samples or analysis of two individual blood spots 
might reduce the observed spread in the lower (1–5 μg/L) 
concentration range. In addition, incurred sample reanal-
ysis (ISR) is recommended for both WB and DBS samples 
to assess the spread of individual patient samples. Two 
major differences present in the study by Willemsen et al. 
are the much broader concentration range of trough con-
centration samples (3.6–28.5 μg/L in WB) and the broader 
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limits of clinical relevance that were used in compari-
son to this study [20]. Because dosing of everolimus in 
patients with cancer is performed in steps of 2.5 mg and 
the target trough concentration range is much wider (up 
to 19.2 μg/L), a larger clinical limit is accepted [38, 39]. In 
transplant patients, dosing can be done in steps of 0.25 mg 
and the target trough concentration range is 3–8 μg/L, 
therefore, a much narrower limit of clinical relevance is 
adjudicated. To the best of our knowledge, no guideline 
is available to determine limits of clinical relevance for 
DBS. The available literature suggests that setting a limit 
of clinical relevance should be done in a multidisciplinary 
team taking into account the clinical application of the 
method, the patient characteristics and the properties of 
the analytical methods [5, 20]. In our study, the everolimus 
DBS method does not meet the limits of clinical relevance 
set by our team and, at this time, cannot replace conven-
tional WB sampling in the TDM of transplant patients 
where low trough concentrations are targeted. For siroli-
mus, Dickerson et al. showed a statistically significant dif-
ference of −0.8 μg/L in the Bland-Altman analysis where 
our method showed no bias [15]. The range of sirolimus 
concentrations in Dickerson et  al. is 4–18 μg/L which is 
higher than the range of 1.7–10.9 μg/L in our study. The 
observed increased bias for higher trough concentrations 
(>10 μg/L) shown in Dickerson et al. might also be present 
using our method. Although results are shown as a ratio, 
samples with a WB concentration of >7.5 μg/L (n = 6) also 
showed lower concentrations in DBS (Figure 1) in this 
study. Excluding these samples yields a slope of 1.04 in 
Passing-Bablok regression, this explains the observed 
slope of 0.86 in the Passing-Bablok regression analysis for 
all sirolimus samples. However, excluding these samples 
does still result in not meeting the limits of clinical rel-
evance. Another possibility is that this is a random phe-
nomenon because the amount of samples with sirolimus 
WB concentration >7.5 μg/L is limited. Additional samples 
in the range of 5–15 μg/L are needed to assess this. For 
sirolimus, the limits of clinical relevance are not met in 
this study and the same trend as for everolimus is present 
where samples with a concentration of 1–5 μg/L showed 
the greatest bias. This might be caused by the same factors 
mentioned before for everolimus. Therefore, at this time, 
the sirolimus DBS method cannot replace conventional 
WB sampling in the TDM of transplant patients with low 
trough concentrations.
In our study the DBS samples were obtained by 
trained phlebotomists at the hospital and not by the 
patients themselves at home. Considering DBS methods 
are intended for home-sampling this might be a limita-
tion of our study. However, the instructions and sampling 
methods are the same for both phlebotomist and patient. 
Patients receive instructions before home sampling is ini-
tiated including practicing a fingerprick under the super-
vision of a trained phlebotomist. This should be sufficient 
for appropriate sampling at home if a patient or caregiver 
is willing and able to perform home sampling, in addition, 
paper and video instruction are available [40].
In the area of transplantation, where narrow 
therapeutic windows are followed for TDM of immu-
nosuppressants, there are strict requirements for the 
analytical performance of assays measuring immuno-
suppressants in blood. With the current data, this clini-
cal DBS validation study showed that not all predefined 
requirements set were met. Although Passing-Bablok 
analysis showed no systematic or constant differences 
between WB and DBS samples, the spread of samples 
did not meet the predefined limits of clinical relevance. 
However, as these limits were set by a local multidis-
ciplinary team these may vary between settings and 
centers [18]. In addition, in a limited resources setting, 
where no WB bioanalytical method exists for sirolimus 
and everolimus, the DBS assay presented here could be 
used to allow TDM. If future studies show optimization 
of DBS assays using ISR, and if logistical challenges sur-
rounding DBS home sampling can be overcome, the DBS 
method could be implemented in routine transplant 
patient care [9, 13, 18]. This would help in reducing 
patient burden, quickly achieving target trough levels 
the first months after transplantation and flexible moni-
toring of graft function.
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